MATERIALS AND METHODS
The two low residual volume nebulizers were studied in a total of three configurations, each aerosolizing 2.5 mg of albuterol sulfate solution in volumes of 3.0 mL (0.083% solution) and 0.5 mL (0.5% solution). The Aeroneb Pro was tested with a standard mouthpiece, and separately with a mouthpiece plus a double oneway valve system and expiratory filter. A prototype of the Aeroneb Go with a mouthpiece was also tested.
Aerosol was delivered to an absolute filter placed between the mouthpiece of the nebulizer and a breath simulator (Hans Rudolph) set to adult breathing parameters (tidal volume 500 mL, rate 15 b/min and inhalation time 35%). (Figure 3 ).
Drug was eluted from the filter, assayed by HPLC, and expressed as percent of total dose (mean ± SD, n=3). Each experiment was performed in triplicate.
RESULTS
The inhaled mass and treatment time for administration of a single dose of 3.0 mL (0.083% solution), and 0.5 mL (0.5% solution) are shown for the Aeroneb Pro with a standard mouthpiece in Table 1 and with the valve system and filter in Table 2 . Data for the Aeroneb Go prototype are shown in Table 3 . Inhaled mass is expressed as the actual amount of drug deposited on the filter and as the percentage of initial dose. All reported values are mean ± SD, n=3.
SUMMARY
Although there was a difference in inhaled mass between nebulizer types, we found relatively no difference in inhaled mass for any nebulizer between the two dose volumes. As expected, the treatment time was substantially shorter with the 0.5 mL dose volume. Reduced treatment time is desirable, particularly in the treatment of acute exacerbation of asthma or COPD. Although comparable inhaled mass can be delivered with shorter treatment time, it is unclear whether the drug concentrations make a difference in airway response. When using these low residual volume nebulizers there is no significant difference in inhaled mass of albuterol sulfate between 3.0 and 0.5 mL doses, which contain the same drug content.
This contrasts with the changes in efficiency with changing dose volumes reported for other small volume nebulizers. There was greater than four fold decrease in the administration time required for the smaller dose volume with the Aeroneb Pro in both configurations and the Aeroneb Go.
CONCLUSION
The Aeroneb Pro and the Aeroneb Go are low residual volume nebulizers; they deliver the same inhaled mass over a range of dose volumes. Use of a lower volume higher concentration solution can reduce the time required for dose administration. 3.0 mL 575 ± ± ± ± 23 µ µ µ µg 23 ± ± ± ± 1% 7 min, 8 s ± ± ± ± 17 s 0.5 mL 540 ± ± ± ± 29µ µ µ µg 22 ± ± ± ± 1% 1 min, 24 s ± ± ± ± 10 s Dose Volume Inhaled Mass µ µ µ µg
FIGURE 2: THE AEROGEN ® ONQ™ AEROSOL GENERATOR (LEFT) WITH A MICROSCOPIC VIEW OF TAPERED APERTURES (UPPER MIDDLE), AND CROSS SECTION OF APERTURES (UPPER RIGHT). HIGH SPEED MICROSCOPIC PHOTOGRAPH OF AEROSOL GENERATED FROM A SINGLE APERTURE (LOWER RIGHT
).
Inhaled Mass % of Dose
Treatment Time (min) 3.0 mL 1084 ± ± ± ± 94 µ µ µ µg 43 ± ± ± ± 4% 6 min, 22 s ± ± ± ± 28 s 0.5 mL 1123 ± ± ± ± 42 µ µ µ µg 45 ± ± ± ± 1% 1 min, 20 s ± ± ± ± 8 s and Aeroneb ® Go Nebulizer (Aeroneb Go), Figure 1) ; both incorporate Aerogen's OnQ™ Aerosol Generator.
The OnQ Aerosol Generator is an electronic micropump ( Figure 2 ) with a residual drug volume as low as 1 microliter. Because of the high efficiency of the aerosolization mechanism, and placement of the drug solution in direct contact with the aerosol generator, the nebulizers' medication cup residual is also low (approximately 0.1 mL).
